Overview : HIV vaccine feasibility studies
- Author
- SHEON, A. R
NIH, national inst. allergy infectious diseases, vaccine trials epidemiology branch, Bethesda MD 20892-7620, United States - Conference title
- Advances in AIDS vaccine development
- Conference name
- National Cooperative Vaccine Development Groups for AIDS. Annual meeting (Alexandria VA 1993-10-30)
- Author (monograph)
- National Cooperaative Vaccine Development Groups for AIDS, United States (Funder/Sponsor)
- Source
AIDS research and human retroviruses. 1994, Vol 10, pp S195-S196 ; SUP2 ; ref : 1 ref
- CODEN
- ARHRE7
- ISSN
- 0889-2229
- Scientific domain
- Immunology, immunopathology, allergology; Microbiology, infectious diseases; Virology
- Publisher
- Liebert, Larchmont, NY
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D01 Immunodeficiencies
- Discipline
- Immunopathology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 3342600
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:42:\"Overview : HIV vaccine feasibility studies\";s:9:\"\u0000*\u0000jtitle\";s:36:\"AIDS research and human retroviruses\";s:9:\"\u0000*\u0000stitle\";s:27:\"AIDS res. hum. retroviruses\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:4:\"S195\";s:8:\"\u0000*\u0000epage\";s:4:\"S196\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0889-2229\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SHEON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHRE7\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:36:\"Advances in AIDS vaccine development\";s:8:\"\u0000*\u0000title\";s:42:\"Overview : HIV vaccine feasibility studies\";s:8:\"\u0000*\u0000place\";s:13:\"Larchmont, NY\";s:6:\"\u0000*\u0000pub\";s:7:\"Liebert\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:42:\"Overview : HIV vaccine feasibility studies\";s:9:\"\u0000*\u0000jtitle\";s:36:\"AIDS research and human retroviruses\";s:9:\"\u0000*\u0000stitle\";s:27:\"AIDS res. hum. retroviruses\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:4:\"S195\";s:8:\"\u0000*\u0000epage\";s:4:\"S196\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0889-2229\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SHEON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHRE7\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:36:\"Advances in AIDS vaccine development\";s:8:\"\u0000*\u0000title\";s:42:\"Overview : HIV vaccine feasibility studies\";s:8:\"\u0000*\u0000place\";s:13:\"Larchmont, NY\";s:6:\"\u0000*\u0000pub\";s:7:\"Liebert\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:42:\"Overview : HIV vaccine feasibility studies\";s:9:\"\u0000*\u0000jtitle\";s:36:\"AIDS research and human retroviruses\";s:9:\"\u0000*\u0000stitle\";s:27:\"AIDS res. hum. retroviruses\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:4:\"S195\";s:8:\"\u0000*\u0000epage\";s:4:\"S196\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0889-2229\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SHEON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHRE7\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:36:\"Advances in AIDS vaccine development\";s:8:\"\u0000*\u0000title\";s:42:\"Overview : HIV vaccine feasibility studies\";s:8:\"\u0000*\u0000place\";s:13:\"Larchmont, NY\";s:6:\"\u0000*\u0000pub\";s:7:\"Liebert\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:42:\"Overview : HIV vaccine feasibility studies\";s:9:\"\u0000*\u0000jtitle\";s:36:\"AIDS research and human retroviruses\";s:9:\"\u0000*\u0000stitle\";s:27:\"AIDS res. hum. retroviruses\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:4:\"S195\";s:8:\"\u0000*\u0000epage\";s:4:\"S196\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0889-2229\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SHEON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHRE7\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:36:\"Advances in AIDS vaccine development\";s:8:\"\u0000*\u0000title\";s:42:\"Overview : HIV vaccine feasibility studies\";s:8:\"\u0000*\u0000place\";s:13:\"Larchmont, NY\";s:6:\"\u0000*\u0000pub\";s:7:\"Liebert\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:42:\"Overview : HIV vaccine feasibility studies\";s:9:\"\u0000*\u0000jtitle\";s:36:\"AIDS research and human retroviruses\";s:9:\"\u0000*\u0000stitle\";s:27:\"AIDS res. hum. retroviruses\";s:7:\"\u0000*\u0000date\";s:4:\"1994\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:4:\"S195\";s:8:\"\u0000*\u0000epage\";s:4:\"S196\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0889-2229\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SHEON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHRE7\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:36:\"Advances in AIDS vaccine development\";s:8:\"\u0000*\u0000title\";s:42:\"Overview : HIV vaccine feasibility studies\";s:8:\"\u0000*\u0000place\";s:13:\"Larchmont, NY\";s:6:\"\u0000*\u0000pub\";s:7:\"Liebert\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
